Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune Inc. is positioned for a positive outlook due to its promising clinical results in treating chronic inflammatory diseases, particularly with its lead candidates, EVO756 and EVO301. The company's novel molecular structure and successful Phase 2 outcomes, including significant patient improvement rates, highlight a strong potential for market expansion, especially into high-value indications like ulcerative colitis and atopic dermatitis. Furthermore, the anticipated first-mover advantage in IL-18 therapies could enhance Evommune's competitive stance within the biopharmaceutical sector, bolstering its long-term revenue prospects.

Bears say

Evommune Inc faces a negative outlook primarily due to its pipeline products, EVO756 and EVO301, which may struggle to achieve peak sales forecasts due to increasing competition in the chronic inflammatory disease market. The company's potential market penetration is further jeopardized by anticipated slower uptake rates and potential hurdles in market access, exacerbated by the presence of competing therapies and alternative treatment options. Additionally, the risks of equity dilution and faster-than-expected generic erosion may add to the financial challenges faced by Evommune, indicating a precarious position in an evolving and competitive landscape.

Evommune Inc (EVMN) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 6 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.